Pharmacyclics (PCYC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacyclics (PCYC)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Gordon James who wrote (503)	8/30/1999 5:57:00 PM
From: Biomaven	Read Replies (1) of 717

Gordon, I was also puzzled by the difference in reported results with the earlier release. Only significant difference I could see is that the earlier results were measured by IVUS (which I think is supposed to be better) rather than by repeated angiograms. There's lots they didn't say here. Just what does "improved" mean when talking about the standardized measurements? Was there a dose-related effect? I'm trying to get hold of the presentation, which might answer some of the questions. The company is in registration, so don't think we'll get much comment from them. I'm not surprised that the Phase II has 2 dose arms - it's too much to hope for that you are going to find the optimum dose in a Phase I. Overall, this still looks fairly promising, though. Standard angioplasty often can't be used here at all as the obstructions aren't localized, and there also seems to be a significant problem with restenosis. Thus I'm pretty convinced that Antrin will eventually find at least a respectable niche here, if not significantly more. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next